Delivering Innovative Treatments to Patients
We need to modernize the FDA to keep pace with scientific discovery and to enable a more competitive, innovative and sustainable ecosystem.
We need to encourage value-driven payment models, and to remove the hurdles making it difficult for innovative, sensible payer/manufacturer arrangements to emerge.
We need to make more information on health care out-of-pocket costs and quality available to patients.
We need to address market distortions like the rapidly growing 340B program or the risk adjuster for commercial insurance that does not account for prescription drug costs.